The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First stage results of a phase II trial of sorafenib plus doxorubicin (SD) in patients (pts) with advanced hepatocellular carcinoma (HCC) who progressed (POD) on sorafenib (S).
 
Ghassan K. Abou-Alfa
Consulting or Advisory Role - Aduro Biotech (I); Astellas Pharma; AstraZeneca (I); Celgene; Celsion; cipla; Exelixis; IntegraGen; Jennerex; Lilly/ImClone; MedImmune; Novartis; Pharmacyclics (I); Sanofi (I); Silenseed (I); Vicus Therapeutics
Research Funding - Abbott Laboratories (Inst); Amgen (Inst); Bayer (Inst); Exelixis (Inst); Genentech (Inst); Lilly/ImClone (Inst); Novartis (Inst); Polaris (Inst); Roche (Inst); Vicus Therapeutics (Inst)
Travel, Accommodations, Expenses - Polaris
 
Marinela Capanu
No Relationships to Disclose
 
Richard Kinh Gian Do
No Relationships to Disclose
 
Ellen Hollywood
No Relationships to Disclose
 
Michele Ly
No Relationships to Disclose
 
Joanne F. Chou
No Relationships to Disclose
 
Jean Kyung Lee
No Relationships to Disclose
 
Louise Catherine Connell
No Relationships to Disclose
 
Peter Justin Wan
No Relationships to Disclose
 
Margaret Bradley
No Relationships to Disclose
 
James J. Harding
No Relationships to Disclose
 
Leonard Saltz
Consulting or Advisory Role - Abbott Biotherapeutics; Bayer; Boehringer Ingelheim; Lilly; pfizer; Roche/Genentech; Sun Pharma
Research Funding - Taiho Pharmaceutical